Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Specifically, carboxamides and oximes can be converted to nitriles by dehydration (elimination of water). Numerous reagents and methodologies are available for this transformation. Methods for nitrile synthesis via dehydration of nitroalkanes have also been described. Phosphorus pentoxide, known since the mid-19th century, is a classical reagent for amide dehydration. Amides can also be dehydrated using trivalent phosphorus reagents such as phosphorus trichloride or triphenyl phosphite; as well as diethyl chlorophosphate, thionyl chloride, or phosgene. In the presence of specific palladium complexes or other suitable catalysts, acetonitrile can function as a dehydrating agent, converting an amide into a nitrile while being transformed into acetamide. Similarly, dichloroacetonitrile may be employed. Related systems utilize iron(II) chloride tetrahydrate, zinc trifluoromethanesulfonate, or uranyl nitrate as catalysts in combination with N-methyl-N-trimethylsilyltrifluoroacetamide as the dehydrating reagent. Carboxylic acid amides can also be dehydrated using a system comprising triphenylphosphane, iodine, and 4-methylmorpholine. Another approach involves high-temperature dehydration (220–240 °C) in hexamethylphosphoramide (HMPA). Dehydration of primary amides with zinc chloride under microwaves is reversible. In aqueous acetonitrile, an amide can be converted to a nitrile; however, in a water–tetrahydrofuran system with added acetamide, the reverse conversion of nitrile to amide occurs.
The amount of YAN that winemakers will see in their grape musts depends on a number of components including grape variety, rootstock, vineyard soils and viticultural practices (such as the use of fertilizers and canopy management) as well as the climate conditions of particular vintages.
In 2004, Gaddafi traveled to the headquarters of the European Union (EU) in Brussels—signifying improved relations between Libya and the EU—and the EU dropped its sanctions on Libya. As a strategic player in Europe's attempts to stem illegal migration from Africa, in October 2010, the EU paid Libya over €50 million to stop African migrants passing into Europe; Gaddafi encouraged the move, saying that it was necessary to prevent the loss of European cultural identity to a new "Black Europe". Gaddafi also completed agreements with the Italian government that they would invest in various infrastructure projects as reparations for past Italian colonial policies in Libya. Italian Prime Minister Silvio Berlusconi gave Libya an official apology in 2006, after which Gaddafi called him the "iron man" for his courage in doing so. In August 2008, Gaddafi and Berlusconi signed a historic cooperation treaty in Benghazi; under its terms, Italy would pay $5 billion to Libya as compensation for its former military occupation. In exchange, Libya would take measures to combat illegal immigration coming from its shores and boost investment in Italian companies. After the US removed Libya from its list of state sponsors of terrorism in 2006, Gaddafi nevertheless continued his anti-Western rhetoric. At the 2008 Arab League summit, held in Syria, he warned fellow Arab leaders that they could be overthrown and executed by the US like Saddam Hussein.
== Causes == When diving, the pressure differences which cause the barotrauma are changes in hydrostatic pressure. There are two components to the surrounding pressure acting on the diver: the atmospheric pressure and the water pressure. A descent of 10 metres (33 feet) in water increases the ambient pressure by an amount approximately equal to the pressure of the atmosphere at sea level. So, a descent from the surface to 10 metres (33 feet) underwater results in a doubling of the pressure on the diver. This pressure change will reduce the volume of a flexible gas-filled space by half. Boyle's law describes the relationship between the volume of the gas space and the pressure in the gas. Barotraumas of descent, also known as compression barotrauma, and squeezes, are caused by preventing the free change of volume of the gas in a closed space in contact with the diver, resulting in a pressure difference between the tissues and the gas space, and the unbalanced force due to this pressure difference causes deformation of the tissues resulting in cell rupture. Barotraumas of ascent, also called decompression barotrauma, are also caused when the free change of volume of the gas in a closed space in contact with the diver is prevented. In this case the pressure difference causes a resultant tension in the surrounding tissues which exceeds their tensile strength. Patients undergoing hyperbaric oxygen therapy must equalize their ears to avoid barotrauma. High risk of otic barotrauma is associated with unconscious patients.
Sources: en.wikipedia.org
=== Health and social impacts === Extreme weather conditions related to the ENSO cycle correlate with changes in the incidence of epidemic diseases like Influenza pandemic, though studies have come to differing conclusions as to whether they are associated with the El Niño or the La Niña phase of the cycle. El Niño cycles are associated with increased risks of some of the diseases transmitted by mosquitoes, such as malaria, dengue fever, and Rift Valley fever, with the latter having a severe outbreak after extreme rainfall in north-eastern Kenya and southern Somalia during the 1997–98 El Niño. Cycles of malaria in India, Venezuela, Brazil, and Colombia have now been linked to El Niño. Outbreaks of another mosquito-transmitted disease, Australian encephalitis (Murray Valley encephalitis—MVE), occur in temperate south-east Australia after heavy rainfall and flooding, which are associated with La Niña events. ENSO conditions have also been related to Kawasaki disease incidence in Japan and the west coast of the United States, via the linkage to tropospheric winds across the north Pacific Ocean. ENSO may be linked to civil conflicts. Scientists at The Earth Institute of Columbia University, having analyzed data from 1950 to 2004, suggest ENSO may have had a role in 21% of all civil conflicts since 1950, with the risk of annual civil conflict doubling from 3% to 6% in countries affected by ENSO during El Niño years relative to La Niña years.
== Artificial de-excitation == 180mTa can be forced to release its energy by X-rays. This was predicted theoretically in 1988 by C. B. Collins, although at that time this de-excitation mechanism had never been observed. This was observed in 180mTa by resonant photo-excitation of intermediate high levels of this nucleus (E ≈ 1 MeV), in 1999 by Belic and co-workers in the Stuttgart nuclear physics group. 178m272Hf is another reasonably stable nuclear isomer, with a half-life of 31 years and a remarkably high excitation energy for that life. In its natural decay, 2.45 MeV is released as gamma rays. As with 180mTa, it is thought that 178m2Hf can be stimulated into releasing its energy. Due to this, the substance has been studied as a possible source for gamma-ray lasers, and reports have indicated that the energy could be released very quickly, so that 178m2Hf can produce extremely high powers (on the order of exawatts). It was supposedly detected experimentally in the 2000s, but it was controversial and not independently confirmed. Other isomers have also been investigated as possible media for gamma-ray stimulated emission.
=== Health === In a February 2026 livestream, part of an interview with The New York Times, Peters listed substances that were part of his daily routine, including testosterone, Accutane, retatrutide, and nebivolol. He began taking testosterone shots at 14. He also told The New York Times that he suspects he is sterile after years of injecting himself with testosterone and alluded to not necessarily enjoying the act of sex. Declaring himself infertile in the past due to testosterone injections, Peters explained: "So it's just like a negative feedback loop when you're not needing to produce testosterone anymore because your body realizes, okay, we're getting it from an outside source." Peters has stated that he is on the autism spectrum, although he has not been professionally diagnosed. He shared in a June 29, 2026, tweet that he used to stalk strangers so he could study neurotypical human behavior:
=== Inorganic === Hemolymph is composed of water, inorganic salts (mostly sodium, chlorine, potassium, magnesium, and calcium), and organic compounds (mostly carbohydrates, proteins, and lipids). The primary oxygen transporter molecule is hemocyanin.
A host–guest complex, also known as a donor–acceptor complex, may be formed from a Lewis base, B, and a Lewis acid, A. The host may be either a donor or an acceptor. In biochemistry host–guest complexes are known as receptor-ligand complexes; they are formed primarily by non-covalent bonding. Many host–guest complexes has 1:1 stoichiometry, but many others have more complex structures. The general equilibrium can be written as
Sources: en.wikipedia.org
=== Special cases === Idiopathic infantile hypercalcemia is caused by a mutation of the CYP24A1 gene, leading to a reduction in the degradation of vitamin D. Infants who have such a mutation have an increased sensitivity to vitamin D and in case of additional intake a risk of hypercalcaemia. The disorder can continue into adulthood.
=== Treatment === When noma is detected early, its progression can be rapidly halted through basic hygiene, antibiotics, and improved nutrition. However, its physical effects are permanent and may require oral and maxillofacial surgery or reconstructive plastic surgery to repair. Treatments for noma in the acute stage include penicillin, sulfonamides, and other antibiotics. In all stages of noma, the World Health Organization encourages antibiotics, vitamin A supplements or other nutritional supplements, a high-protein diet, and proper hydration. The World Health Organization recommends using amoxicillin and metronidazole in tandem to treat stage I noma (acute necrotizing gingivitis), along with the use of chlorhexidine and hydrogen peroxide to clean the mouth and gums. For stage II noma (edema phase), stage III noma (acute/gangrenous stage), and stage IV noma (scarring phase), the WHO recommends either one of two therapies. The first therapy includes the concurrent use of amoxicillin, clavulanic acid, gentamicin, and metronidazole. The second option includes the concurrent use of ampicillin, gentamicin, and metronidazole. For both options, chlorhexidine mouthwash is advised. For stage III and IV noma, the use of ketamine, and honey are both given as options for dressing the lesions. Reconstruction is usually very challenging and should be delayed until full recovery (usually about one year following initial intervention).
In Vietnam, iced coffee (Vietnamese: cà phê đá, lit. 'iced coffee') is a traditional Vietnamese coffee recipe. It is created using coffee roasted between medium and dark. The drink is made by passing hot water through the grounds into a cup that already contains condensed milk. To serve the drink cold, ice is added to the cup. Variations involve additions of ice, sugar or condensed milk. A popular variation is cà phê sữa đá (or nâu đá in the North), which is iced coffee served with sweetened condensed milk. This is done by putting two to three teaspoons or more of condensed milk into the cup prior to the drip filter process.
== Further reading == The Folger Way: Coffee Pioneering Since 1850, by Ruth Waldo Newhall (1910–2003), married to Scott Newhall (1914–1992), late of the San Francisco Chronicle, J.A. Folger (publisher) (1961); OCLC 5838971
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.